BIOMAT Database Logo BIOMAT Database Logo

[Incidence of second non-hematologic malignancies in patients with multiple myeloma]. 2010

M Fernández-Ruiz, and J M Guerra-Vales, and J Llenas-García, and F Colina-Ruiz Delgado

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D016609 Neoplasms, Second Primary Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause. Neoplasms, Metachronous,Neoplasms, Metachronous Second Primary,Neoplasms, Therapy-Related,Neoplasms, Treatment-Related,Second Malignancy,Second Neoplasm,Second Primary Neoplasms,Therapy-Associated Neoplasms,Therapy-Related Cancer,Treatment-Associated Neoplasms,Treatment-Related Cancer,Cancer, Second Primary,Metachronous Neoplasms,Metachronous Second Primary Neoplasms,Neoplasms, Therapy-Associated,Neoplasms, Treatment-Associated,Second Cancer,Second Primary Neoplasms, Metachronous,Therapy-Associated Cancer,Therapy-Related Neoplasms,Treatment-Associated Cancer,Treatment-Related Neoplasms,Cancer, Second,Cancer, Therapy-Associated,Cancer, Therapy-Related,Cancer, Treatment-Associated,Cancer, Treatment-Related,Cancers, Second,Cancers, Second Primary,Cancers, Therapy-Associated,Cancers, Therapy-Related,Cancers, Treatment-Associated,Cancers, Treatment-Related,Malignancies, Second,Malignancy, Second,Metachronous Neoplasm,Neoplasm, Metachronous,Neoplasm, Second,Neoplasm, Second Primary,Neoplasm, Therapy-Associated,Neoplasm, Therapy-Related,Neoplasm, Treatment-Associated,Neoplasm, Treatment-Related,Neoplasms, Second,Neoplasms, Therapy Associated,Neoplasms, Therapy Related,Neoplasms, Treatment Associated,Neoplasms, Treatment Related,Second Cancers,Second Malignancies,Second Neoplasms,Second Primary Cancer,Second Primary Cancers,Second Primary Neoplasm,Therapy Associated Cancer,Therapy Associated Neoplasms,Therapy Related Cancer,Therapy Related Neoplasms,Therapy-Associated Cancers,Therapy-Associated Neoplasm,Therapy-Related Cancers,Therapy-Related Neoplasm,Treatment Associated Cancer,Treatment Associated Neoplasms,Treatment Related Cancer,Treatment Related Neoplasms,Treatment-Associated Cancers,Treatment-Associated Neoplasm,Treatment-Related Cancers,Treatment-Related Neoplasm

Related Publications

M Fernández-Ruiz, and J M Guerra-Vales, and J Llenas-García, and F Colina-Ruiz Delgado
Second malignancies in patients with multiple myeloma.
January 1977, Oncology,
M Fernández-Ruiz, and J M Guerra-Vales, and J Llenas-García, and F Colina-Ruiz Delgado
Multiple myeloma and second malignancies.
April 2014, Clinical lymphoma, myeloma & leukemia,
M Fernández-Ruiz, and J M Guerra-Vales, and J Llenas-García, and F Colina-Ruiz Delgado
[Clinical analysis of multiple myeloma with second primary malignancies and multiple myeloma secondary to malignancies].
August 2022, Zhonghua yi xue za zhi,
M Fernández-Ruiz, and J M Guerra-Vales, and J Llenas-García, and F Colina-Ruiz Delgado
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.
September 2023, Cancers,
M Fernández-Ruiz, and J M Guerra-Vales, and J Llenas-García, and F Colina-Ruiz Delgado
[Incidence of tuberculosis in patients with hematologic malignancies].
January 1995, Pneumonologia i alergologia polska,
M Fernández-Ruiz, and J M Guerra-Vales, and J Llenas-García, and F Colina-Ruiz Delgado
[Hematologic Malignancies/Pediatric Malignancies. III. Treatment of Relapsed/Refractory Multiple Myeloma].
May 2016, Gan to kagaku ryoho. Cancer & chemotherapy,
M Fernández-Ruiz, and J M Guerra-Vales, and J Llenas-García, and F Colina-Ruiz Delgado
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.
September 2016, Leukemia & lymphoma,
M Fernández-Ruiz, and J M Guerra-Vales, and J Llenas-García, and F Colina-Ruiz Delgado
[Hematologic Malignancies/Pediatric Malignancies Update on Novel Treatment Strategies in Multiple Myeloma].
May 2020, Gan to kagaku ryoho. Cancer & chemotherapy,
M Fernández-Ruiz, and J M Guerra-Vales, and J Llenas-García, and F Colina-Ruiz Delgado
Second primary malignancies in multiple myeloma: A review.
March 2021, Blood reviews,
M Fernández-Ruiz, and J M Guerra-Vales, and J Llenas-García, and F Colina-Ruiz Delgado
Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma.
May 2022, European journal of haematology,
Copied contents to your clipboard!